1921
Volume 103, Issue 1_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The Schistosomiasis Consortium for Operational Research (SCORE) was funded in 2008 to improve the evidence base for control and elimination of schistosomiasis—better understanding of the systemic morbidities experienced by children in schistosomiasis-endemic areas and the response of these morbidities to treatment, being essential for updating WHO guidelines for mass drug administration (MDA) in endemic areas. This article summarizes the SCORE studies that aimed to gauge the impact of MDA-based treatment on schistosomiasis-related morbidities. Morbidity cohort studies were embedded in the SCORE’s larger field studies of gaining control of schistosomiasis in Kenya and Tanzania. Following MDA, cohort children had less undernutrition, less portal vein dilation, and increased quality of life in Year 5 compared with baseline. We also conducted a pilot study of the Behavioral Assessment System for Children (BASC-2) in conjunction with the Kenya gaining control study, which demonstrated beneficial effects of treatment on classroom behavior. In addition, the SCORE’s Rapid Answers Project performed systematic reviews of previously available data, providing two meta-analyses related to morbidity. The first documented children’s infection-related deficits in school attendance and achievement and in formal tests of learning and memory. The second showed that greater reductions in egg output following drug treatment correlates significantly with reduced odds of most morbidities. Overall, these SCORE morbidity studies provided convincing evidence to support the use of MDA to improve the health of school-aged children in endemic areas. However, study findings also support the need to use enhanced metrics to fully assess and better control schistosomiasis-associated morbidity.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0830
2020-05-12
2020-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/103/1_Suppl/tpmd190830.html?itemId=/content/journals/10.4269/ajtmh.19-0830&mimeType=html&fmt=ahah

References

  1. Colley DG, Jacobson JA, Binder S, 2020. Schistosomiasis Consortium for Operational Research and Evaluation (SCORE): its foundations, development, and evolution. Am J Trop Med Hyg 103 (Suppl 1): 513.
    [Google Scholar]
  2. King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG, 2011. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 5: e1321.
    [Google Scholar]
  3. King CH, Dickman K, Tisch DJ, 2005. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365: 15611569.
    [Google Scholar]
  4. Galappaththi-Arachchige HN et al., 2018. Evaluating diagnostic indicators of urogenital Schistosoma haematobium infection in young women: a cross sectional study in rural South Africa. PLoS One 13: e0191459.
    [Google Scholar]
  5. Whitty CJ, Mabey DC, Armstrong M, Wright SG, Chiodini PL, 2000. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg 94: 531534.
    [Google Scholar]
  6. Kvalsvig JD, 1986. The effects of schistosomiasis haematobium on the activity of school children. J Trop Med Hyg 89: 8590.
    [Google Scholar]
  7. Terer CC, Bustinduy AL, Magtanong RV, Muhoho N, Mungai PL, Muchiri EM, Kitron U, King CH, Mutuku FM, 2013. Evaluation of the health-related quality of life of children in Schistosoma haematobium-endemic communities in Kenya: a cross-sectional study. PLoS Negl Trop Dis 7: e2106.
    [Google Scholar]
  8. Kinung’hi S, Magnussen P, Kaatano G, Olsen A, 2016. Infection with Schistosoma mansoni has an effect on quality of life, but not on physical fitness in schoolchildren in Mwanza region, north-western Tanzania: a cross-sectional study. PLoS Negl Trop Dis 10: e0005257.
    [Google Scholar]
  9. Leenstra T, Coutinho HM, Acosta LP, Langdon GC, Su L, Olveda RM, McGarvey ST, Kurtis JD, Friedman JF, 2006. Schistosoma japonicum reinfection after praziquantel treatment causes anemia associated with inflammation. Infect Immun 74: 63986407.
    [Google Scholar]
  10. Stephenson LS, Latham MC, Kurz KM, Kinoti SN, 1989. Single dose metrifonate or praziquantel treatment in Kenyan children. II. Effects on growth in relation to Schistosoma haematobium and hookworm egg counts. Am J Trop Med Hyg 41: 445453.
    [Google Scholar]
  11. Assis AM, Barreto ML, Prado MS, Reis MG, Parraga IM, Blanton RE, 1998. Schistosoma mansoni infection and nutritional status in schoolchildren: a randomized, double-blind trial in northeastern Brazil. Am J Clin Nutr 68: 12471253.
    [Google Scholar]
  12. Malhotra I, LaBeaud AD, Morris N, McKibben M, Mungai P, Muchiri E, King CL, King CH, 2018. Cord blood antiparasite interleukin 10 as a risk marker for compromised vaccine immunogenicity in early childhood. J Infect Dis 217: 14261434.
    [Google Scholar]
  13. Ondigo BN et al., 2018. Impact of mothers' schistosomiasis status during gestation on children’s IgG antibody responses to routine vaccines 2 years later and anti-schistosome and anti-malarial responses by neonates in western Kenya. Front Immunol 9: 1402.
    [Google Scholar]
  14. Ezeamama AE, Bustinduy AL, Nkwata AK, Martinez L, Pabalan N, Boivin MJ, King CH, 2018. Cognitive deficits and educational loss in children with schistosome infection-A systematic review and meta-analysis. PLoS Negl Trop Dis 12: e0005524.
    [Google Scholar]
  15. Musuva R, Shen Y, Wei X, Binder S, Ivy JA, Secor WE, Montgomery SP, King CH, Mwinzi PNM, 2017. Change in children’s school behavior after mass administration of praziquantel for Schistosoma mansoni infection in endemic areas of western Kenya: a pilot study using the Behavioral Assessment System for Children (BASC-2). PLoS One 12: e0181975.
    [Google Scholar]
  16. Giboda M, Bergquist NR, 1999. Post-transmission schistosomiasis. Parasitol Today 15: 307308.
    [Google Scholar]
  17. Leutscher PD, Ramarokoto CE, Hoffmann S, Jensen JS, Ramaniraka V, Randrianasolo B, Raharisolo C, Migliani R, Christensen N, 2008. Coexistence of urogenital schistosomiasis and sexually transmitted infection in women and men living in an area where Schistosoma haematobium is endemic. Clin Infect Dis 47: 775782.
    [Google Scholar]
  18. Miller-Fellows SC, Howard L, Kramer R, Hildebrand V, Furin J, Mutuku FM, Mukoko D, Ivy JA, King CH, 2017. Cross-sectional interview study of fertility, pregnancy, and urogenital schistosomiasis in coastal Kenya: documented treatment in childhood is associated with reduced odds of subfertility among adult women. PLoS Negl Trop Dis 11: e0006101.
    [Google Scholar]
  19. Wall KM et al., 2018. Schistosomiasis is associated with incident HIV transmission and death in Zambia. PLoS Negl Trop Dis 12: e0006902.
    [Google Scholar]
  20. WHO, 2006. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  21. WHO, 2013. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Geneva, Switzerland: World Health Organization, 81.
    [Google Scholar]
  22. Murray CJL, Lopez AD, 1996. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard School of Public Health/World Bank.
    [Google Scholar]
  23. Hotez PJ et al., 2014. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis 8: e2865.
    [Google Scholar]
  24. GBD 2016 Disease Injury and Incidence and Prevalence Collaborators, 2017. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390: 12111259.
    [Google Scholar]
  25. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, 2006. Disease Control Priorities in Developing Countries 2/e. New York, NY: Oxford University Press.
    [Google Scholar]
  26. Shen Y et al., 2017. Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries. BMC Infect Dis 17: 652.
    [Google Scholar]
  27. Hofstraat K, van Brakel WH, 2016. Social stigma towards neglected tropical diseases: a systematic review. Int Health 8 (Suppl 1): i53i70.
    [Google Scholar]
  28. Bustinduy AL, King CH, 2009. Parasitic helminths. Fratamico PM, Smith JL, Brogden KA, eds. Post-Infectious Sequelae and Long-Term Consequences of Infectious Diseases. Washington, DC: American Society for Microbiology Press, 291329.
    [Google Scholar]
  29. King CH et al., 2020. Impact of different mass drug administration strategies for gaining and sustaining control of Schistosoma mansoni and Schistosoma haematobium infection in Africa. Am J Trop Med Hyg 103 (Suppl 1): 1423.
    [Google Scholar]
  30. Bustinduy AL, Parraga IM, Thomas CL, Mungai PL, Mutuku F, Muchiri EM, Kitron U, King CH, 2013. Impact of polyparasitic infections on anemia and undernutrition among Kenyan children living in a Schistosoma haematobium-endemic area. Am J Trop Med Hyg 88: 433440.
    [Google Scholar]
  31. Parraga IM, Assis AM, Prado MS, Barreto ML, Reis MG, King CH, Blanton RE, 1996. Gender differences in growth of school-aged children with schistosomiasis and geohelminth infection. Am J Trop Med Hyg 55: 150156.
    [Google Scholar]
  32. Ezeamama AE, McGarvey ST, Acosta LP, Zierler S, Manalo DL, Wu HW, Kurtis JD, Mor V, Olveda RM, Friedman JF, 2008. The synergistic effect of concomitant schistosomiasis, hookworm, and Trichuris infections on children’s anemia burden. PLoS Negl Trop Dis 2: e245.
    [Google Scholar]
  33. Righetti AA, Adiossan LG, Ouattara M, Glinz D, Hurrell RF, N'Goran EK, Wegmuller R, Utzinger J, 2013. Dynamics of anemia in relation to parasitic infections, micronutrient status, and increasing age in south-central Cote d’Ivoire. J Infect Dis 207: 16041615.
    [Google Scholar]
  34. Leger L, Lambert J, Goulet A, Rowan C, Dinelle Y, 1984. Capacité aérobie des Québécois de 6 à 17 ans - test navette de 20 mètres avec paliers de 1 minute. Can J Appl Sport Sci 9: 6469.
    [Google Scholar]
  35. Leger LA, Lambert J, 1982. A maximal multistage 20-m shuttle run test to predict VO2 max. Eur J Appl Physiol Occup Physiol 49: 112.
    [Google Scholar]
  36. Leger LA, Mercier D, Gadoury C, Lambert J, 1988. The multistage 20 metre shuttle run test for aerobic fitness. J Sports Sci 6: 93101.
    [Google Scholar]
  37. Varni JW, Burwinkle TM, Seid M, Skarr D, 2003. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 3: 329341.
    [Google Scholar]
  38. Andrade G, Bertsch DJ, Gazzinelli A, King CH, 2017. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: a systematic review and meta-analysis. PLoS Negl Trop Dis 11: e0005372.
    [Google Scholar]
  39. Richter J, Hatz C, Campagne G, Bergquist NR, Jenkins JM, 2000. Ultrasound in Schistosomiasis: A Practical Guide to the Standardized Use of Ultrasonography for the Assessment of Schistosomiasis-Related Morbidity. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  40. Samuels AM, Matey E, Mwinzi PN, Wiegand RE, Muchiri G, Ireri E, Hyde M, Montgomery SP, Karanja DM, Secor WE, 2012. Schistosoma mansoni morbidity among school-aged children: a SCORE project in Kenya. Am J Trop Med Hyg 87: 874882.
    [Google Scholar]
  41. Mohamed I, Kinung’hi S, Mwinzi PNM, Onkanga IO, Andiego K, Muchiri G, Odiere MR, Vennervald BJ, Olsen A, 2018. Diet and hygiene practices influence morbidity in schoolchildren living in schistosomiasis endemic areas along Lake Victoria in Kenya and Tanzania-A cross-sectional study. PLoS Negl Trop Dis 12: e0006373.
    [Google Scholar]
  42. Sircar AD, Mwinzi PNM, Onkanga IO, Wiegand RE, Montgomery SP, Secor WE, 2018. Schistosoma mansoni mass drug administration regimens and their effect on morbidity among schoolchildren over a 5-year period-Kenya, 2010–2015. Am J Trop Med Hyg 99: 362369.
    [Google Scholar]
  43. Olsen A, Kinung’hi S, Kaatano G, Magnussen P, 2020. Changes in morbidity, physical fitness, and perceived quality of life among schoolchildren following four years of different mass drug administration strategies against Schistosoma mansoni infection in Mwanza region, northwestern Tanzania. Am J Trop Med Hyg 102: 100105.
    [Google Scholar]
  44. Shen Y et al., 2019. Five year impact of different multi-year mass drug administration strategies on childhood Schistosoma mansoni-associated morbidity: a combined analysis from SCORE cohort studies in the Lake Victoria regions of Kenya and Tanzania. Am J Trop Med Hyg 101: 13361344.
    [Google Scholar]
  45. King CH, Kittur N, Wiegand RE, Shen Y, Ge Y, Whalen CC, Campbell C, Hattendorf J, Binder S, 2020. Challenges in protocol development and interpretation of the Schistosomiasis Consortium for Operational Research and Evaluation intervention studies. Am J Trop Med Hyg 103 (Suppl 1): 3641.
    [Google Scholar]
  46. Majid MF, Kang SJ, Hotez PJ, 2019. Resolving “worm wars”: an extended comparison review of findings from key economics and epidemiological studies. PLoS Negl Trop Dis 13: e0006940.
    [Google Scholar]
  47. Verani JR, Abudho B, Montgomery SP, Mwinzi PN, Shane HL, Butler SE, Karanja DM, Secor WE, 2011. Schistosomiasis among young children in Usoma, Kenya. Am J Trop Med Hyg 84: 787791.
    [Google Scholar]
  48. Bustinduy AL, Friedman JF, Kjetland EF, Ezeamama AE, Kabatereine NB, Stothard JR, King CH, 2016. Expanding praziquantel (PZQ) access beyond mass drug administration programs: paving a way forward for a pediatric PZQ formulation for schistosomiasis. PLoS Negl Trop Dis 10: e0004946.
    [Google Scholar]
  49. Kittur N, Castleman JD, Campbell CH Jr., King CH, Colley DG, 2016. Comparison of Schistosoma mansoni prevalence and intensity of infection, as determined by the circulating cathodic antigen urine assay or by the Kato-Katz fecal assay: a systematic review. Am J Trop Med Hyg 94: 605610.
    [Google Scholar]
  50. Mwinzi PN, Kittur N, Ochola E, Cooper PJ, Campbell CH Jr., King CH, Colley DG, 2015. Additional evaluation of the point-of-contact circulating cathodic antigen assay for Schistosoma mansoni infection. Front Public Health 3: 48.
    [Google Scholar]
  51. King CH, Bertsch D, Andrade GM, Burnim M, Ezeamama AE, Binder S, Colley DG, 2020. The Schistosomiasis Consortium for Operational Research and Evaluation Rapid Answers Project: systematic reviews and meta-analysis to provide policy recommendations based on available evidence. Am J Trop Med Hyg 103 (Suppl 1): 9296.
    [Google Scholar]
  52. Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A, 1998. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 92: 9093.
    [Google Scholar]
  53. Satayathum SA, Muchiri EM, Ouma JH, Whalen CC, King CH, 2006. Factors affecting infection or reinfection with Schistosoma haematobium in coastal Kenya: survival analysis during a nine-year, school-based treatment program. Am J Trop Med Hyg 75: 8392.
    [Google Scholar]
  54. Gryseels B et al., 2001. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 6: 864873.
    [Google Scholar]
  55. Lo NC, Gurarie D, Yoon N, Coulibaly JT, Bendavid E, Andrews JR, King CH, 2018. Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis. Proc Natl Acad Sci USA 115: E584E591.
    [Google Scholar]
  56. Bustinduy AL, Wright S, Joekes EC, Kabatereine NB, Reinhard-Rupp J, King CH, Stothard JR, 2017. One hundred years of neglect in paediatric schistosomiasis. Parasitology 144: 16131623.
    [Google Scholar]
  57. Baird S, Hicks JH, Kremer M, Miguel E, 2016. Worms at work: long-run impacts of a child health investment. Q J Econ 131: 16371680.
    [Google Scholar]
  58. Colley DG et al., 2020. Contributions of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) to Schistosomiasis control and elimination: key findings and messages for future goals, thresholds, and operational research. Am J Trop Med Hyg 103 (Suppl 1): 125134.
    [Google Scholar]
  59. Murray CJ, 1996. Rethinking DALYs. Murray CJ, Lopez AD, eds. The Global Burden of Disease. Cambridge, MA: Harvard School of Public Health/World Bank, 198.
    [Google Scholar]
  60. Walker M et al., 2016. New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel. Parasit Vectors 9: 41.
    [Google Scholar]
  61. Neglected Tropical Diseases Support Center, 2019. MORBID: Morbidity Operational Research for Bilharziasis Implementation Decisions (Pilot). Available at: https://www.ntdsupport.org/cor-ntd/ntd-connector/morbid-morbidity-operational-research-bilharziasis-implementation-decisions. Accessed January 22, 2020.
    [Google Scholar]
  62. Corstjens PL et al., 2020. Circulating Anodic Antigen (CAA): a highly sensitive diagnostic biomarker to detect active Schistosoma infections—improvement and use during SCORE. Am J Trop Med Hyg 103 (Suppl 1): 5057.
    [Google Scholar]
  63. Clements MN et al., 2018. Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi. Parasit Vectors 11: 111.
    [Google Scholar]
  64. de Vlas SJ, Engels D, Rabello AL, Oostburg BF, Van Lieshout L, Polderman AM, Van Oortmarssen GJ, Habbema JD, Gryseels B, 1997. Validation of a chart to estimate true Schistosoma mansoni prevalences from simple egg counts. Parasitology 114: 113121.
    [Google Scholar]
  65. de Vlas SJ, Gryseels B, 1992. Underestimation of Schistosoma mansoni prevalences. Parasitol Today 8: 274277.
    [Google Scholar]
  66. Savioli L, Hatz C, Dixon H, Kisumku UM, Mott KE, 1990. Control of morbidity due to Schistosoma haematobium on Pemba Island: egg excretion and hematuria as indicators of infection. Am J Trop Med Hyg 43: 289295.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0830
Loading

Supplemental files

  • Received : 06 Nov 2019
  • Accepted : 26 Jan 2020
  • Published online : 12 May 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error